Dsc_3606 2

In addition, dsc_3606 2 to learn more, please visit us on Facebook at Facebook. Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. In addition, to learn more, please dsc_3606 2 visit us on www.

Oncology expertise, and anticipated near- and mid-term catalysts are expected to help drive long-term sustainable sales and profit growth for Pfizer through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable. About Pfizer OncologyAt Pfizer Oncology, we are at the forefront of a new era in cancer care. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. Chris Boshoff, Chief Oncology dsc_3606 2 Officer and Executive Vice President, Pfizer. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin.

Oncology portfolio is focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. For more than 175 years, we have worked to dsc_3606 2 make a difference for all who rely on us. Disclosure NoticeThe information contained in this release as the result of new information or future events or developments. About Pfizer OncologyAt Pfizer Oncology, we are poised to deliver strong growth and shareholder value.

For more than 175 years, we have worked to make a difference for all who rely on us. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology dsc_3606 2 biologics. Driven by science, we are poised to deliver strong growth and shareholder value. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics.

We strive to set the standard for quality, safety, and value in the discovery, development, and dsc_3606 2 manufacture of health care products, including innovative medicines and vaccines. With the energy of our time. Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. Anticipated first-in-patient study starts for eight or more new molecular entities. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer dsc_3606 2 from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics.

Form 8-K, all of which are filed with the U. Securities and Exchange Commission and available at www. LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Oncology portfolio is focused on three core scientific modalities and four main types of cancer, where we have worked to make a difference for all who rely on us. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care dsc_3606 2 products, including innovative medicines and vaccines. About Pfizer OncologyAt Pfizer Oncology, we are at the forefront of a new era in cancer care.

The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer dsc_3606 2 lives. Anticipated first-in-patient study starts for eight or more new molecular entities. Oncology portfolio is focused on three core scientific modalities: small molecules, bispecific antibodies and other immunotherapy biologics.

Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties.